IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
1-Year Return
17.25%
This Quarter Return
-7.62%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$297M
AUM Growth
-$31.7M
(-9.6%)
Cap. Flow
-$15.4M
Cap. Flow
% of AUM
-5.17%
Top 10 Holdings %
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$8.41M |
| 2 |
uniQure
QURE
|
$8.23M |
| 3 |
Biogen
BIIB
|
$7.51M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$7.34M |
| 5 |
Gilead Sciences
GILD
|
$6.67M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.9M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$11.8M |
| 3 |
Amgen
AMGN
|
$10.2M |
| 4 |
Harmony Biosciences
HRMY
|
$8.39M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.93M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$13.7B
| $3.25M | 1.09% |
28,877
-40,000
| -58% | -$4.5M |
|
27
Sarepta Therapeutics
SRPT
$1.94B
| $3.23M | 1.09% |
26,700
+7,900
| +42% | +$957K |
|
28
Rocket Pharmaceuticals
RCKT
$346M
| $3.19M | 1.08% |
156,000
| – | – |
|
29
Denali Therapeutics
DNLI
$2.19B
| $3.17M | 1.07% |
154,000
-34,000
| -18% | -$700K |
|
30
AstraZeneca
AZN
$253B
| $3.15M | 1.06% |
+46,500
| New | +$3.15M |
|
31
Xenon Pharmaceuticals
XENE
$2.97B
| $3.12M | 1.05% |
91,500
+66,000
| +259% | +$2.25M |
|
32
CRISPR Therapeutics
CRSP
$4.81B
| $2.86M | 0.96% |
+63,000
| New | +$2.86M |
|
33
Madrigal Pharmaceuticals
MDGL
$9.55B
| $2.67M | 0.9% |
18,300
| – | – |
|
34
Legend Biotech
LEGN
$6.45B
| $2.55M | 0.86% |
38,000
| – | – |
|
35
Halozyme
HALO
$8.6B
| $2.38M | 0.8% |
62,200
-33,300
| -35% | -$1.27M |
|
|
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $2.34M | 0.79% |
290,000
+200,000
| +222% | +$1.61M |
|
|
ONC
37
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.2B
| $2.28M | 0.77% |
12,700
+4,000
| +46% | +$719K |
|
38
Jazz Pharmaceuticals
JAZZ
$7.77B
| $2.23M | 0.75% |
17,200
| – | – |
|
39
Mirum Pharmaceuticals
MIRM
$3.73B
| $2.13M | 0.72% |
67,500
| – | – |
|
40
Iovance Biotherapeutics
IOVA
$792M
| $2.02M | 0.68% |
445,000
+380,000
| +585% | +$1.73M |
|
41
Ionis Pharmaceuticals
IONS
$9.42B
| $1.95M | 0.66% |
43,000
| – | – |
|
42
Zai Lab
ZLAB
$3.33B
| $1.92M | 0.65% |
78,958
| – | – |
|
43
Genmab
GMAB
$16.7B
| $1.56M | 0.53% |
+44,300
| New | +$1.56M |
|
44
Celldex Therapeutics
CLDX
$1.51B
| $1.32M | 0.45% |
48,099
| – | – |
|
45
Cogent Biosciences
COGT
$1.81B
| $1.31M | 0.44% |
+135,000
| New | +$1.31M |
|
46
Dyne Therapeutics
DYN
$1.86B
| $1.23M | 0.41% |
137,751
-163,000
| -54% | -$1.46M |
|
47
NovoCure
NVCR
$1.34B
| $1.19M | 0.4% |
74,000
+42,000
| +131% | +$677K |
|
48
Amicus Therapeutics
FOLD
$2.44B
| $1.09M | 0.37% |
+90,000
| New | +$1.09M |
|
49
Cytokinetics
CYTK
$6.01B
| $1.09M | 0.37% |
37,000
| – | – |
|
50
Guardant Health
GH
$7.51B
| $1.08M | 0.36% |
36,500
| – | – |
|